ING Group’s PTC Therapeutics PTCT Stock Holding History

ING Group’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-35,000	Closed	-$405K	–	595
2016 Q3	$405K	Buy	+35,000	New	+$285K	﹤0.01%	451

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

ING Group's PTCT Position: Q4 2016 in Review

ING Group sold out of PTC Therapeutics (PTCT) in Q4 2016, closing a stake of 35,000 shares — an estimated $405K sold.

ING Group first reported a position in PTCT in Q3 2016 and held it in 1 quarter. The position peaked at $405K in Q3 2016. 123 funds tracked by Wall St. Rank hold PTCT as of Q4 2016.

ING Group reported no remaining PTC Therapeutics position as of Q4 2016 after selling out during the quarter.
ING Group sold 35,000 PTC Therapeutics shares in Q4 2016, an estimated $405K.
ING Group first reported a position in PTC Therapeutics in Q3 2016 and held it in 1 quarter.
ING Group's PTC Therapeutics position peaked at $405K in Q3 2016.
123 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2016.

Based on ING Group's 13F filing for Q4 2016, filed 6 Feb 2017.